Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000929638-25-004298·Lind Global Fund II LP
Schedule 13G ownership disclosure
Tenax Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 88032L605
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Lind Global Fund II LP
Shares: 442,480 · Class: 8.8%
- Lind Global Partners II LLC
Shares: 442,480 · Class: 8.8%
- EASTON JEFF
Shares: 442,480 · Class: 8.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-25-004298
- Form type
- SCHEDULE 13G/A
- Filer
- Lind Global Fund II LP
- CIK
- CIK 1871665
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership